Welcome to our dedicated page for Bolt Biotherapeutics news (Ticker: BOLT), a resource for investors and traders seeking the latest updates and insights on Bolt Biotherapeutics stock.
Bolt Biotherapeutics, Inc. (BOLT) is a clinical-stage biopharmaceutical company specializing in novel immunotherapies for cancer treatment. Originating from Dr. Engleman's lab at Stanford University, the company leverages groundbreaking technology to develop tumor-targeted therapies, capitalizing on the combined power of the innate and adaptive immune systems. Backed by top-tier life sciences investors, Bolt is on a promising growth trajectory, dedicated to bringing innovative and curative therapies to patients.
The company’s proprietary Boltbody™ ISAC (Immune-Stimulating Antibody Conjugate) platform is the cornerstone of its therapeutic pipeline, which includes candidates like BDC-1001 and BDC-3042. This platform merges tumor-targeting antibodies with immune-stimulating linker-payloads designed to reprogram the tumor microenvironment, fostering a robust anti-cancer response.
BDC-1001 targets HER2-positive cancers and has shown durable clinical responses and a favorable safety profile in Phase 1 trials. Notably, the FDA granted Orphan Drug Designation to BDC-1001 for gastric cancer treatment, underlining its potential to address unmet medical needs. Phase 2 trials are underway for various cancers, including breast, colorectal, and endometrial cancers.
BDC-3042 targets Dectin-2, a receptor expressed by tumor-associated macrophages (TAMs), and aims to convert these cells from tumor-supportive to tumor-destructive. Having received FDA clearance for its Investigational New Drug (IND) application, BDC-3042 is set to enter Phase 1 trials.
Bolt's pipeline also includes multiple Boltbody ISAC collaboration programs with leading biopharmaceutical companies, further validating its platform technology. The company’s financial health is robust, with strategic plans to fund ongoing and future clinical programs.
For more information, visit Bolt Biotherapeutics, Inc. website.
Bolt Biotherapeutics (BOLT) reported Q3 2024 financial results, highlighting progress in its cancer immunotherapy programs. The company advanced to the highest dose level in BDC-3042's Phase 1 trial and presented updated preclinical data for BDC-4182 at SITC. Q3 revenue was $1.1 million, down from $2.5 million in Q3 2023. R&D expenses decreased to $13.8 million from $15.0 million, while G&A expenses reduced to $3.8 million from $5.8 million. The company reported an operational loss of $16.4 million. With $84.4 million in cash, funding is expected to last through mid-2026.
Bolt Biotherapeutics (BOLT) presented updated preclinical data for BDC-4182, their next-generation Boltbody™ ISAC targeting claudin 18.2, and findings from Phase 1 dose-escalation trial of BDC-1001 at SITC. BDC-4182 showed superior efficacy compared to claudin 18.2 ADCs in preclinical studies, demonstrating anti-tumor activity across various models and acceptable safety in non-human primates. The company plans to initiate clinical trials in 2025. The Phase 1 BDC-1001 trial revealed that greater immune activation was associated with clinical benefit, particularly in patients with high HER2 antigen expression, supporting the development of next-generation ISACs with enhanced immune activation.
Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company, has announced changes to its Board of Directors. Jakob Dupont, M.D., Executive Partner at Sofinnova Investments, has been appointed to the board, bringing over 20 years of experience in oncology and immuno-oncology. Concurrently, Dr. Jim Healy is stepping down as Lead Independent Director, Frank D. Lee is departing the board, and Brian O'Callaghan, CEO of Deep Genomics, will assume the role of Chair.
Dr. Dupont's extensive background includes leadership roles at Atara Biotherapeutics, Gossamer Bio, and Genentech/Roche, where he was instrumental in developing several successful cancer therapies. His appointment is expected to benefit Bolt's pipeline advancement and collaborations. The company is currently conducting a clinical trial with a first-in-class Dectin-2 agonist and has a near-clinical ISAC program targeting Claudin 18.2.
Bolt Biotherapeutics (BOLT), a clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapies, has announced its participation in two major conferences this September. The company will be featured in:
1. A fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 6, 2024, at 7:00 a.m. EDT.
2. A company presentation at the H.C. Wainwright 26th Annual Global Investment Conference, available from September 9, 2024, at 7:00 a.m. EDT.
Both presentations will be accessible via webcast on Bolt's website, with replays available for 30 days after each event. This participation demonstrates Bolt's commitment to engaging with investors and showcasing its progress in the competitive field of cancer immunotherapy.
Bolt Biotherapeutics (Nasdaq: BOLT) reported Q2 2024 financial results and provided a business update. Key highlights include:
1. Advancement to cohort 6 in the Phase 1 study of BDC-3042 for advanced cancers.
2. Acceptance of an abstract for BDC-4182, a claudin 18.2-targeting Boltbody ISAC, at the SITC 39th Annual Meeting.
3. Cash balance of $97.5 million as of June 30, 2024, expected to fund operations through mid-2026.
4. Q2 2024 financial results: Collaboration revenue of $1.3 million, R&D expenses of $15.4 million, G&A expenses of $4.9 million, and a loss from operations of $22.6 million.
5. Ongoing collaborations with Genmab and Toray continue to progress.
Bolt Biotherapeutics (Nasdaq: BOLT) announced its Q1 2024 financial results, revealing a strategic pipeline prioritization and leadership changes. The company will focus on its Phase 1 Dectin-2 agonist antibody BDC-3042 and its next-gen Boltbody™ ISAC platform, including the new clinical candidate BDC-4182 targeting Claudin 18.2. Development of trastuzumab imbotolimod (BDC-1001) will halt, and the workforce will be cut by approximately 50% to extend the cash runway into the second half of 2026.
Willie Quinn replaces Randall Schatzman as CEO, with other leadership promotions announced. Financially, Bolt reported collaboration revenue of $5.3 million, up from $1.8 million in Q1 2023, and a loss from operations of $17.1 million, down from $18.4 million the previous year. R&D expenses increased to $16.5 million, driven by higher clinical trial costs. G&A expenses rose slightly to $5.8 million. The company will host a webcast to discuss these changes.
FAQ
What is the current stock price of Bolt Biotherapeutics (BOLT)?
What is the market cap of Bolt Biotherapeutics (BOLT)?
What is Bolt Biotherapeutics, Inc.?
What is the Boltbody™ ISAC platform?
What are BDC-1001 and BDC-3042?
What recent achievements has Bolt Biotherapeutics made?
Who backs Bolt Biotherapeutics?
What is the significance of Orphan Drug Designation for BDC-1001?
What are the goals of the BDC-3042 program?
What partnerships does Bolt Biotherapeutics have?
How is Bolt Biotherapeutics advancing its clinical programs?
Where can I find more information about Bolt Biotherapeutics?
